# US 2014/0154801 A1 · Endocrine precursor cells, pancreativ hormone-expressing cells and methos of production > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154801 A1 - Document ID: US20140154801A1 - Status: Published application - Kind: A1 - Application number: 14/072,491 - Filed: 2013-11-05 - Published: 2014-06-05 - Earliest claimed: 2006-03-02 - Assignees: ViaCyte, Inc. - Applicants: ViaCyte, Inc. - Inventors: Kevin A. D'Amour; Anne Bang; Emmanuel E. Baetge - Web page: https://patentgrep.com/patent/US20140154801A1 ## CPC - C12N 5/0676: {Pancreatic cells} - A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36) - A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/48: of the pancreatic hormones - C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells} - C12N 2500/38: Vitamins - C12N 2501/10: Growth factors - C12N 2501/105: Insulin-like growth factors [IGF] - C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2) - C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 - C12N 2501/12: Hepatocyte growth factor [HGF] - C12N 2501/15: Transforming growth factor beta (TGF-β) - C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance - C12N 2501/33: Insulin - C12N 2501/335: Glucagon; Glucagon-like peptide [GLP]; Exendin - C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] - C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor) - C12N 2501/415: Wnt; Frizzeled - C12N 2501/42: Notch; Delta; Jagged; Serrate - C12N 2501/58: Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) - C12N 2501/734: Proteases (EC 3.4.) - C12N 2501/999: Small molecules not provided for elsewhere - C12N 2506/02: from embryonic cells - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations. ## Claims ### Claim at position 1 1-20. (canceled) ### Claim 21 A population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein said markers are pancreatic duodenal homeobox 1(PDX1) and NKX6 transcription factor related locus 1 (NKX6.1) or pancreas specific transcription factor 1a(PTF1A). ### Claim 22 (depends on 1) The cell population of claim 1, wherein said population is derived from a human pluripotent stem cell. ### Claim 23 (depends on 1) The cell population of claim 1, wherein said population is in contact with a gamma secretase inhibitor. ### Claim 24 (depends on 1) The cell population of claim 1, wherein said population is in contact with a retinoid. ### Claim 25 (depends on 1) The cell population of claim 1, wherein said population is in contact with noggin. ### Claim 26 (depends on 1) The cell population of claim 1, wherein said markers are PDX1 and NKX6.1. ### Claim 27 (depends on 1) The cell population of claim 1, wherein said markers are PDX1, NKX6.1 and PTF1A. ### Claim 28 (depends on 1) The cell population of claim 1, wherein the population does not substantially express INS or GCG. ### Claim 29 An in vitro cell culture comprising pancreatic endoderm cells that express a marker selected from the group consisting of PDX1, NKX6.1 and PTF1A. ### Claim 30 (depends on 29) The cell culture of claim 29, wherein said cells are in contact with a retinoid. ### Claim 31 (depends on 29) The cell culture of claim 29, wherein said cells are in contact with noggin. ### Claim 32 (depends on 29) The cell culture of claim 29, wherein said pancreatic endoderm cells express PDX1 and NKX6.1. ### Claim 33 (depends on 29) The cell culture of claim 29, wherein said cells are in contact with a gamma secretase inhibitor. ### Claim 34 (depends on 29) The cell culture of claim 29, wherein the pancreatic endoderm cells do not substantially express INS or GCG. ### Claim 35 An in vitro differentiated population of pancreatic endoderm cells obtained from the differentiation of pluripotent stem cells, wherein the population expresses PDX1 and NKX6.1 or PTF1A. ### Claim 36 (depends on 35) The cell population of claim 35, wherein said pluripotent stem cell is an embryonic stem cell. ### Claim 37 (depends on 35) The cell population of claim 35, wherein said population is in contact with a gamma secretase inhibitor. ### Claim 38 (depends on 35) The cell population of claim 35, wherein said population is in contact with a retinoid. ### Claim 39 (depends on 35) The cell population of claim 35, wherein said population is in contact with noggin. ### Claim 40 (depends on 35) The cell population of claim 35, wherein said population does not substantially express INS or GCG.